Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Immunochemical fecal occult blood tests for colorectal cancer screening

A Population-based Comparison of Immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening

News image

Quantitative fecal immunochemical tests identify individuals with colorectal cancer with greater levels of accuracy than guaiac tests.

Dr Thibaut Raginel and colleagues from France collected fecal samples from 19,797 individuals in France who participated in a colorectal cancer screening program, from 2009 through 2011.

The research team analyzed samples using the Magstream and OC Sensor fecal immunochemical testss, as well as the Hemoccult II guaiac test.

Colonoscopies were performed for patients with positive results from all 3 tests.

The research team reported that the cut-off values for levels of hemoglobin in buffer and stools were 55 ng/mL and 180 μg/g for the Magstream and 150 ng/mL and 30 μg/g for the OC Sensor, respectively.

Results from the fecal immunochemical testss were compared with those from the guaiac test for cut-off values for stool samples, positivity rates, and the receiver operating characteristic curve values.

The numbers needed to screen and the numbers needed to scope to detect an advanced neoplasia were calculated.

The team of doctors found a positive test result in 1224 participants, and 1075 underwent a colonoscopy examination.

Of these, 334 were found to have advanced neoplasia.

The true-positive rate for OC Sensor fecal immunochemical testss was 0.90%
Gastroenterology

Considering the cut-off values associated with the positivity rate of Hemoccult II, the numbers needed to screen were 239 for Hemoccult II, 166 for a 1-sample Magstream fecal immunochemical tests, and 129 for a 1-sample OC Sensor fecal immunochemical tests; the numbers needed to scope were 3.3, 2.3, and 1.8, respectively.

For the same false-positive rate as Hemoccult II, the true-positive rates for Magstream and OC Sensor fecal immunochemical testss were 0.65% and 0.90% respectively, compared with 0.42% for Hemoccult II.

The OC Sensor fecal immunochemical tests had a greater area under the receiver operating characteristic curve value than the Magstream fecal immunochemical tests.

Dr Raginel's team commented, "Based on results from a large, population-based study, the OC Sensor fecal immunochemical tests identifies patients with colorectal cancer with greater accuracy than the Magstream fecal immunochemical tests."

Gastroenterology 2013: (144)5 :918-925
08 May 2013

Go to top of page Email this page Email this page to a colleague

 27 January 2015

Advanced search
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 27 January 2015 
Outcomes for liver transplantation
 26 January 2015 
Antidepressants and GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us